High clinical development costs coupled with declining drug discovery success rates have meant that pharmaceutical companies must re-evaluate their drug development process in order to reduce attrition rates and remain competitive. Over the next decade biomarkers will change the way in which pharma companies determine the economic viability of their drug discovery process. The use of biomarkers to aid the discovery of promising products will create an enhanced understanding of the clinical development process and help to facilitate the shift towards 'personalized medicine'. 'Commercial Opportunities from Biomarkers: Transforming drug discovery, clinical development and molecular diagnostics' is the latest addition to the drug discovery series, examining recent developments and applications within the biomarkers field. Using up-to-date case studies to indicate best practice strategies, this report will ensure that you are able streamline your R&D process and identify potential cost savings throughout drug discovery and development. Regulatory changes are analyzed and recent alliances are examined, enabling you to understand the role and future of this fast-moving field.